As of 1:28pm ET
| +0.06 / +1.19%|
The 4 analysts offering 12-month price forecasts for Melinta Therapeutics Inc have a median target of 70.00, with a high estimate of 75.00 and a low estimate of 65.00. The median estimate represents a +1,275.25% increase from the last price of 5.09.
The current consensus among 5 polled investment analysts is to Buy stock in Melinta Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.